Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
477 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
GlaxoSmithKline plc - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'GlaxoSmithKline plc - Product Pipeline Review - 2014', provides an overview of the GlaxoSmithKline plc's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of GlaxoSmithKline plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of GlaxoSmithKline plc including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of GlaxoSmithKline plc's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the GlaxoSmithKline plc's pipeline products Reasons to buy - Evaluate GlaxoSmithKline plc's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of GlaxoSmithKline plc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the GlaxoSmithKline plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of GlaxoSmithKline plc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of GlaxoSmithKline plc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of GlaxoSmithKline plc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 GlaxoSmithKline plc Snapshot 9 GlaxoSmithKline plc Overview 9 Key Information 9 Key Facts 9 GlaxoSmithKline plc - Research and Development Overview 10 Key Therapeutic Areas 10 GlaxoSmithKline plc - Pipeline Review 24 Pipeline Products by Stage of Development 24 Pipeline Products - Monotherapy 25 Pipeline Products - Combination Treatment Modalities 26 Pipeline Products - Partnered Products 27 Pipeline Products - Out-Licensed Products 31 GlaxoSmithKline plc - Pipeline Products Glance 33 GlaxoSmithKline plc - Late Stage Pipeline Products 33 GlaxoSmithKline plc - Clinical Stage Pipeline Products 38 GlaxoSmithKline plc - Early Stage Pipeline Products 52 GlaxoSmithKline plc - Drug Profiles 55 (umeclidinium bromide + vilanterol trifenatate) 55 eltrombopag olamine 57 Flu Pandemic Vaccine 60 fluticasone furoate 62 influenza virus vaccine quadrivalent 65 tenofovir disoproxil fumarate 67 trametinib 69 (dabrafenib + trametinib) 72 pazopanib hydrochloride 74 (fluticasone furoate + vilanterol trifenatate) 78 albiglutide 80 alitretinoin 83 ambrisentan 85 astuprotimut-R 87 belimumab 88 darapladib 91 GSK-1437173A 93 GSK-1562902A 95 GSK-2132231A 97 GSK-257049 99 GSK-2696273 102 KD-295 103 lapatinib ditosylate 104 measles, mumps and rubella vaccine (live) 107 mepolizumab 108 ofatumumab 110 recMAGE-A3 + AS15 114 umeclidinium bromide 116 vilanterol trifenatate 118 zanamivir 120 tafenoquine 122 (fluticasone furoate + levocabastine hydrochloride) 124 (fluticasone furoate + umeclidinium) 125 AD-02 126 afuresertib 128 Antisense Oligonucleotide for Transthyretin Amyloidosis 130 batefenterol 131 camicinal 133 dabrafenib 135 danirixin 137 dilmapimod 139 fiboflapon 141 firategrast 143 foretinib 145 GSK-1070806 147 GSK-1278863 148 GSK-1322322 150 GSK-1399686 152 GSK-2140944 153 GSK-217744 154 GSK-2189242A 155 GSK-2231392A 157 GSK-2245035 158 GSK-2269557 160 GSK-2285921 161 GSK-2302024A 163 GSK-2302032A 164 GSK-2330672 165 GSK-2339345 166 GSK-239512 167 GSK-249320 168 GSK-256073 170 GSK-2586184 171 GSK-2586881 173 GSK-2696274 174 GSK-2696275 175 GSK-2789869A 176 GSK-2830929A 177 GSK-2830930A 178 GSK-2838497A 179 GSK-2890457 180 GSK-3196165 181 GSK-598809 183 GSK-692342 185 GSK-732462 187 GSK-933776 188 levocabastine hydrochloride 189 losmapimod 190 mapatumumab 192 maribavir 195 Nimenrix 197 otelixizumab 200 ozanezumab 202 ProCvax 203 Recombinant Vector Vaccine for Malaria 204 retosiban 206 rilapladib 208 ronacaleret hydrochloride 209 S. Pneumoniae Next Generation Vaccine 211 trametinib + dabrafenib + panitumumab 212 trametinib + uprosertib 213 afuresertib + trametinib 215 GSK-2302025A 216 GSK-2636771 217 GSK-525762 218 (amlodipine + enalapril maleate) 219 (amlodipine + losartan) 221 (amlodipine + rosuvastatin) 222 (candesartan cilexetil + hydrochlorothiazide) 223 (fluticasone furoate + umeclidinium + vilanterol) 224 AD-01 226 AD-03 227 Ad35-GRIN Vaccine + Adjuvanted HIV Vaccine 229 DENV-1 PIV 230 epelsiban besylate 231 exenatide 233 FP-1039 234 GLPG-0555 236 GSK-1070916A 238 GSK-1940029 239 GSK-1995057 240 GSK-2130579A 241 GSK-2241658A 242 GSK-2256098 243 GSK-2256098 + trametinib 244 GSK-2256294 245 GSK-2315698 246 GSK-2315698 + GSK-2398852 247 GSK-2330672 + GSK-1614235 248 GSK-2374697 249 GSK-2392019A 250 GSK-2392102A 251 GSK-2392103A 252 GSK-2392105A 253 GSK-2392106A 254 GSK-2398852 255 GSK-2434735 256 GSK-2647544 257 GSK-2654909A 258 GSK-2654911A 259 GSK-2789868-A 260 GSK-2793660 261 GSK-2798745 262 GSK-2800528 263 GSK-2816126 264 GSK-2838232 265 GSK-2838500A 266 GSK-2838501A 267 GSK-2849330 268 GSK-2849466 269 GSK-2857916 270 GSK-2862277 271 GSK-2878175 272 GSK-2879552 273 GSK-2881078 274 GSK-2981710 275 GSK-3003891A 276 GSK-3003892A 277 GSK-3003893A 278 GSK-3003895A 279 GSK-3003896A 280 GSK-3003898A 281 GSK-3003899A 282 GSK-3050002 283 GSK-3117391 284 GSK-3206640A 285 GSK-3206641-A 286 HIV Prophylactic Vaccine 287 HIV Vaccine 288 omipalisib 289 RSV-001 290 TerCvax 291 uprosertib 293 Antibody Drug Conjugate for Cancer 294 BLyS-Gelonin Fusion Toxin for Cancer 295 Cancer Vaccine 296 Ebola And Marburg Vaccine 297 GSK-2041706 298 GSK-2225745 299 GSK-2578215A 300 GSK-2656157 302 IMP-731 303 Influenza Vaccine 305 Monoclonal Antibodies to Activate OX40 Receptors for Cancer 306 Monophosphoryl Lipid A Vaccine for Alzheimer's Disease 307 Proteosome-Based Vaccine for Alzheimer's Disease 308 Small Molecule1 to Inhibit Histone Methyltransferases for Cancer 309 Small Molecule2 to Inhibit Histone Methyltransferases for Cancer 310 Small Molecule3 to Inhibit Histone Methyltransferases for Cancer 311 Small Molecules For Malaria 312 Small Molecules to Inhibit Gyrase for Mycobacterium Tuberculosis Infections 313 Tuberculosis Vaccine 314 Antibodies Targeting an Immune Checkpoint for Cancer 315 Drug for Chronic Liver Disease 316 Drug to Inhibit Kynurenine 3-Monooxygenase for Acute Pancreatitis 317 GSK-J1 318 Small Molecule for Tuberculosis 319 Small Molecule to Inhibit Histone Deacetylases for Cancer 320 Small Molecules to Inhibit Falcipain for Malaria 321 Small Molecules to Inhibit InhA for Tuberculosis 322 Small Molecules to Inhibit Leucyl-tRNA Synthetase for Tuberculosis 323 Small Molecules to Inhibit RNA Polymerase for Hepatitis C 324 GlaxoSmithKline plc - Pipeline Analysis 325 GlaxoSmithKline plc - Pipeline Products by Target 325 GlaxoSmithKline plc - Pipeline Products by Route of Administration 332 GlaxoSmithKline plc - Pipeline Products by Molecule Type 334 GlaxoSmithKline plc - Pipeline Products by Mechanism of Action 336 GlaxoSmithKline plc - Recent Pipeline Updates 344 GlaxoSmithKline plc - Dormant Projects 413 GlaxoSmithKline plc - Discontinued Pipeline Products 434 Discontinued Pipeline Product Profiles 435 GlaxoSmithKline plc - Company Statement 447 GlaxoSmithKline plc - Locations And Subsidiaries 450 Head Office 450 Other Locations & Subsidiaries 450 GlaxoSmithKline plc - Key Manufacturing Facilities 461 Appendix 462 Methodology 462 Coverage 462 Secondary Research 462 Primary Research 462 Expert Panel Validation 462 Contact Us 463 Disclaimer 463
List of Tables GlaxoSmithKline plc, Key Information 23 GlaxoSmithKline plc, Key Facts 23 GlaxoSmithKline plc - Pipeline by Indication, 2014 25 GlaxoSmithKline plc - Pipeline by Stage of Development, 2014 38 GlaxoSmithKline plc - Monotherapy Products in Pipeline, 2014 39 GlaxoSmithKline plc - Combination Treatment Modalities in Pipeline, 2014 40 GlaxoSmithKline plc - Partnered Products in Pipeline, 2014 41 GlaxoSmithKline plc - Partnered Products/ Combination Treatment Modalities, 2014 42 GlaxoSmithKline plc - Out-Licensed Products in Pipeline, 2014 45 GlaxoSmithKline plc - Out-Licensed Products/ Combination Treatment Modalities, 2014 46 GlaxoSmithKline plc - Pre-Registration, 2014 47 GlaxoSmithKline plc - Filing rejected/Withdrawn, 2014 48 GlaxoSmithKline plc - Phase III, 2014 49 GlaxoSmithKline plc - Phase II, 2014 52 GlaxoSmithKline plc - Phase I, 2014 59 GlaxoSmithKline plc - Preclinical, 2014 66 GlaxoSmithKline plc - Discovery, 2014 68 GlaxoSmithKline plc - Pipeline by Target, 2014 339 GlaxoSmithKline plc - Pipeline by Route of Administration, 2014 347 GlaxoSmithKline plc - Pipeline by Molecule Type, 2014 349 GlaxoSmithKline plc - Pipeline Products by Mechanism of Action, 2014 350 GlaxoSmithKline plc - Recent Pipeline Updates, 2014 358 GlaxoSmithKline plc - Dormant Developmental Projects,2014 427 GlaxoSmithKline plc - Discontinued Pipeline Products, 2014 448 GlaxoSmithKline plc, Other Locations 464 GlaxoSmithKline plc, Subsidiaries 464 GlaxoSmithKline plc, Key Manufacturing Facilities 475
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
